| Title |
Profile of abemaciclib and its potential in the treatment of breast cancer
|
|---|---|
| Published in |
OncoTargets and therapy, August 2018
|
| DOI | 10.2147/ott.s149245 |
| Pubmed ID | |
| Authors |
James M Martin, Lori J Goldstein |
| Abstract |
Hormone-receptor-positive breast cancer is the most common subtype of breast cancer among patients with both early-stage and metastatic disease. Recent advances in the understanding of its pathophysiology have led to the discovery and utilization of targeted inhibitors to cyclin-dependent kinases 4 and 6 (CDK4/6). There are currently three available CDK4/6 inhibitors available for use in USA: palbociclib, ribociclib, and abemaciclib. Their oral administration and tolerable toxicities make this class of agents appealing to both patients and health care providers. Abemaciclib, the most recently approved CDK4/6 inhibitor, has unique pharmacologic properties and potential toxicities. This review highlights the current understanding of abemaciclib and discusses its current and future roles in the treatment of breast cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 55 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 15% |
| Student > Ph. D. Student | 7 | 13% |
| Researcher | 5 | 9% |
| Student > Bachelor | 5 | 9% |
| Student > Doctoral Student | 4 | 7% |
| Other | 8 | 15% |
| Unknown | 18 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 9 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 15% |
| Medicine and Dentistry | 5 | 9% |
| Chemistry | 3 | 5% |
| Nursing and Health Professions | 2 | 4% |
| Other | 6 | 11% |
| Unknown | 22 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 September 2018.
All research outputs
#22,986,241
of 25,628,260 outputs
Outputs from OncoTargets and therapy
#2,093
of 3,012 outputs
Outputs of similar age
#299,792
of 342,601 outputs
Outputs of similar age from OncoTargets and therapy
#75
of 114 outputs
Altmetric has tracked 25,628,260 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,012 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,601 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 114 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.